SERUM SORUBLE CD27 LEVEL DETERMINES CLINICAL OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN RITUXIMAB ERA

被引：0
|
作者：
Coto, N.
Tsurumi, H. [1 ]
Kanemura, N. [1 ]
Kasahara, S. [1 ]
Hara, T. [1 ]
Kito, Y. [2 ]
Takami, T. [2 ]
Moriwaki, H. [1 ]
Nakamura, H. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu, Japan
[2] Gifu Univ, Grad Sch Med, Dept Immunopathol, Gifu, Japan
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0671
引用
收藏
页码：281 / 281
页数：1
相关论文
共 50 条
  • [21] Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Macon, William R.
    Ristow, Kay M.
    Allmer, Cristine
    Slager, Susan L.
    Witzig, Thomas E.
    Cerhan, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 412 - 417
  • [22] Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era
    Liang, Xiping
    Hu, Renzhi
    Li, Qiying
    Wang, Chaoyu
    Liu, Yao
    EXPERIMENTAL HEMATOLOGY, 2023, 122 : 1 - 9
  • [23] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [24] Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.
    Hayama, Miyuki
    Okamoto, Masataka
    Hagiwara, Yuki
    Tanae, Ken
    Kohri, Mika
    Takahashi, Naoki
    Yoshino, Tadashi
    Ohshima, Koichi
    Niitsu, Nozomi
    BLOOD, 2010, 116 (21) : 752 - 752
  • [25] IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
    Chen, Xiangli
    Zang, Yuzhu
    Li, Dujuan
    Guo, Jianmin
    Wang, Yacai
    Lin, Yuqi
    Wei, Zhenghong
    MEDICINE, 2020, 99 (21) : E19883
  • [26] Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era
    Telio, David
    Villa, Diego
    Shenkier, Tamara
    Sehn, Laurie H.
    Klasa, Richard
    Tan, King
    Gascoyne, Randy D.
    Connors, Joseph M.
    Savage, Kerry J.
    BLOOD, 2011, 118 (21) : 354 - 354
  • [27] Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era
    Kridel, Robert
    Telio, David
    Villa, Diego
    Sehn, Laurie H.
    Gerrie, Alina S.
    Shenkier, Tamara
    Klasa, Richard
    Slack, Graham W.
    Tan, King
    Gascoyne, Randy D.
    Connors, Joseph M.
    Savage, Kerry J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 210 - 221
  • [28] Serum B-cell activating factor (BAFF) in diffuse large B-cell lymphoma: Its prognostic significance in the rituximab era
    Kim, Seok Jin
    Sung, Hwa Jung
    Choi, Chul Won
    Kim, In Sun
    Kim, Byung Soo
    Yoon, Soo-Young
    Won, Jong-Ho
    Kim, Jun Suk
    BLOOD, 2007, 110 (11) : 470A - 471A
  • [29] Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
    Seo, Seyoung
    Hong, Jung Yong
    Yoon, Shinkyo
    Yoo, Changhoon
    Park, Ji Hyun
    Lee, Jung Bok
    Park, Chan-Sik
    Huh, Jooryung
    Lee, Yoonse
    Kim, Kyung Won
    Ryu, Jin-Sook
    Kim, Seok Jin
    Kim, Won Seog
    Yoon, Dok Hyun
    Suh, Cheolwon
    ONCOTARGET, 2016, 7 (47) : 76934 - 76943
  • [30] PROPOSAL OF NEW PROGNOSTIC INDEX FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
    Yoon, S.
    Yoon, D. H.
    Kim, S.
    Lee, K.
    Kang, E. H.
    Lee, S. W.
    Park, C. J.
    Park, C. S.
    Huh, J.
    Suh, C.
    HAEMATOLOGICA, 2015, 100 : 403 - 404
12345